From professional translators, enterprises, web pages and freely available translation repositories.
no benefit was observed in the low and very low risk groups.
zema un ļoti zema riska grupās ieguvums netika konstatēts.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
no benefit is attributed to subsequent years.
uz turpmākajiem gadiem neattiecina nekādus pabalstus.
Last Update: 2014-11-21
Usage Frequency: 2
Quality:
no benefit to the economic activities of the club
kluba saimnieciskās darbības rezultātā neiegūtais labums
Last Update: 2014-11-21
Usage Frequency: 1
Quality:
vaccination of felv positive cats is of no benefit.
fe lv pozitīvu kaķu vakcinācijai nav efekta.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
there is no benefit in the amendments, which only weaken the conclusions.
nav nekāda labuma no grozījumiem, kuri tikai vājina secinājumus.
Last Update: 2012-03-01
Usage Frequency: 4
Quality:
no benefit was observed for mace or all cause mortality .
ieguvumu mace vai jebkāda cēloņa mirstības ziņā nekonstatēja.
Last Update: 2017-04-26
Usage Frequency: 2
Quality:
no benefit was observed for mace or all-cause mortality.
netika novērots ieguvums saistībā ar mace vai jebkura iemesla izraisītas nāves sastopamību.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
no benefits
ieguvumu nav
Last Update: 2017-04-06
Usage Frequency: 1
Quality:
if the recipient is a carrier of hbsag, there is no benefit in administering this medicinal product.
ja recipients ir hbsag nēsātājs, šo zāļu ievadīšana nav lietderīga.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
this temporary and extraordinary step is designed to end human suffering by showing clearly that there is no benefit in following the route offered by the smugglers.
Šis pagaidu un ārkārtas pasākums ir paredzēts, lai izbeigtu cilvēku ciešanas, skaidri demonstrējot, ka nav nekāda labuma doties pa cilvēku kontrabandistu piedāvāto maršrutu.
it is not recommended to co- administer efavirenz and viramune, because of additive toxicity and no benefit in terms of efficacy over either nnrti alone.
turklāt šāda vienlaicīga lietošana neuzlabo efektivitāti, salīdzinot ar nnrti monoterapiju.
in contrast to progression free survival time, no benefit in overall survival time could be demonstrated in patients with kps ≤ 80 who were 65 years of age or older.
salīdzinot ar dzīvildzi bez slimības progresēšanas, netika novērots kopējās dzīvildzes ieguvums pacientiem ar kps ≤ 80, kuri bija 65 gadu vecumā vai vecāki.
in the her2-negative population, there was no benefit in pfs when letrozole plus tyverb was compared with letrozole plus placebo (see table 6).
her2-negatīvajā populācijā, salīdzinot letrozolu un tyverb ar letrozolu un placebo, pfs uzlabošanās netika konstatēta (skatīt 6. tabulu).